UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C 20549  FORM
10-Q  (Mark One)  [X] QUARTERLY
REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly
period ended March 31, 2010  [
 ] TRANSITION
REPORT UNDER SECTION 13 OR 15(d) OF THE EXCHANGE ACT For the transition
period from ____ to ____  Commission File No.
333-144226  ARTVENTIVE MEDICAL GROUP, INC.(Exact name of
registrant as specified in its charter)  Nevada 26-0148468 (State
or other jurisdiction (IRS
Employer of
incorporation or organization) Identification
No.)  1797 Playa Vista, San Marcos, California, 92078 (Address
of principal executive offices)  (760) 471-7700 (Registrants telephone number)  URANIUM
PLUS RESOURCE CORPORATION (Former
name, former address and former fiscal year, if changed since last report)  Indicate by check mark whether the registrant (1) has filed all
reports required to be filed by Section 13 or 15(d) of the Exchange Act during
the past 12 months (or for such shorter period that the registrant was required
to file such reports), and (2) has been subject to such filing requirements for
the past 90 days.  Yes  [x]  No  [  ]  Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any, every Interactive
Data File required to be submitted and posted pursuant to Rule 405 of Regulation
S-T during the preceding 12 months (or for such shorter period that the
registrant was required to submit and post such files). Yes [  ] No [ X ] Not Required  Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller
reporting company.  See the definitions of large accelerated filer,
accelerated filer and smaller reporting company in Rule 12b-2 of the Exchange
Act.  Large accelerated filer [  ] Accelerated filer [  ] Non-accelerated filer [  ] Smaller reporting company [ X ]  Indicate by check mark whether the registrant is a shell company
(as defined in Rule 12b-2 of the Exchange Act).  Yes [  ]  No
[x]   State
the number of shares outstanding of each of the issuers classes of common
equity, as of the latest practicable date:  As of
March 31, 2010, there were 46,760,534 shares of the Companys common stock
issued and outstanding.   PART I  FINANCIAL INFORMATION  Item 1.
 Financial Statements.          ArtVentive Medical Group Inc. (formerly Uranium Plus Resource Corporation) Financial Statements (Unaudited) For the Period from January 23, 2007 (Inception) to March 31,
2010                   Balance
Sheets as of March 31, 2010 (unaudited) and December 31, 2009 Statement
1  Statements of
Operations and Comprehensive Loss (unaudited) for the three month periods ended March 31, 2010
and March 31, 2009; and
the period from January 23, 2007 (Inception) through March 31, 2010 Statement
2  Statements of Cash
Flows (unaudited)for the three month periods ended March 31, 2010 and March 31
2009; and
for the period from January 23, 2007 (Inception) to March 31, 2010 Statement
3  Statements of Changes
in Stockholders Equity (Deficit) (unaudited) for the period from January
23, 2007 (Inception) to March 31, 2010 Statement
4  Notes to Financial
Statements (unaudited)


Statement 1 ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Balance Sheets March
31, 2010 and December 31, 2009   ASSETS
March 31,2010
(unaudited)
December 31,
2009CURRENTCash
and cash equivalents
$
1,110,025
$
60,791TOTAL
CURRENT ASSETS
1,110,025
60,791PROPERTY
,PLANT AND EQUIPMENTOFFICE
EQUIPMENT
3,389NET
PROPERTY, PLANT AND EQUIPMENT
3,389TOTAL
ASSETS
$
1,113,414
$
60,791LIABILITIES AND STOCKHOLDERS EQUITY (DEFICIT)CURRENTAccounts
payable
$
6,179
$
4,411Accrued
management fees
18,333
-Convertible
note payable (Note 5)
-
150,000TOTAL
LIABILITIES
24,512
154,411STOCKHOLDERS
EQUITY (DEFICIT)Common
stock, par value $.001, 100,000,000 sharesauthorized,
46,760,534 shares issued and outstanding after
giving
effect to 5.8 for 1 split on April 22, 2008 and
1.65
for 1 split on February 12, 2010
46,760
21,430Additional
paid in capital
1,314,143
89,473Deficit
accumulated during the development stage
(272,001)
(204,523)TOTAL
STOCKHOLDERS EQUITY (DEFICIT)
1,088,902
(93,620)TOTAL
LIABILITIES AND STOCKHOLDERS
EQUITY
(DEFICIT)
$
1,113,414
$
60,791  (See
accompanying notes)


Statement 2 ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statements of
Operations and Comprehensive Loss (Unaudited) For
the Three Months Ended March 31, 2010 and March 31, 2009; and for the Period
from January 23, 2007 (Inception) to March 31, 2010   For the three months ended March 31, 2010
For the three months ended
March 31, 2009
For the period from January 23, 2007 (Inception) to March
31, 2010REVENUES
$
NIL
$
NIL
$
NILOPERATING
EXPENSESExploration
costs
-
-
45,533Research
and development
10,000
-
10,000Selling,
general and administrative
58,260
10,555
216,734Depreciation
expense
-
-
516OPERATING
LOSS BEFORE OTHER ITEMS AND INCOME TAX
(68,260)
(10,555)
(272,783)OTHER
INCOME/(EXPENSE)INTEREST
INCOME
782
-
782Income
tax expense (benefit)
-
-
-NET
LOSS AVAILABLE TO COMMON STOCKHOLDERS
(67,478)
(10,555)
(272,001)COMPREHENSIVE
LOSS FOR THE PERIOD
$
(67,478)
$
(10,555)
$
(272,001)BASIC
AND DILUTED LOSS PER COMMON SHARE
(0.00)
(0.00)WEIGHTED
AVERAGE SHARES OUTSTANDING
42,498,204
21,430,200     Statement
3 ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statements of Cash
Flows (Unaudited) For
the Three Months Ended March 31, 2010 and March 31, 2009; and for the Period
from January 23, 2007 (Inception) to March 31, 2010   For the three months ended March 31, 2010
For the three months ended
March 31,
2009
For the period  from January 23, 2007 (Inception) to
March 31,
2010CASH
FLOW FROM OPERATING ACTIVITIESNet
loss
$
(67,478)
$
(10,555)
$
(272,001)ADJUSTMENTS
TO RECONCILE NET LOSS TO NET CASH USED BY OPERATING ACTIVITIESNon-cash
expenses
-
-
60,805Depreciation
expense
-
-
516CHANGES
IN OPERATING ASSETS AND LIABILITIESAccounts
payable
1,768
4,089
6,179Accrued
management fees
18,333
-
18,333Accounts
payable  related party
-
-
39,000NET
CASH USED BY OPERATING ACTIVITIES
(47,377)
(6,466)
(147,168)CASH
FLOWS FROM INVESTING ACTIVITIESDisposal
of equipment
-
-
745Purchase
of equipment
(3,389)

(4,632)NET
CASH USED, BY INVESTING ACTIVITIES
(3,389)
-
(3,887)CASH
FLOWS FROM FINANCING ACTIVITIESIssuance
of common stock for cash
1,100,000
-
1,111,080Convertible
note payable (see Note 5)
-
-
150,000NET
CASH PROVIDED, BY FINANCING ACTIVITIES
1,100,000
-
1,261,080NET
INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS
1,049,234
(6,466)
1,110,025CASH,
BEGINNING OF PERIOD
60,791
93,139
-CASH,
END OF PERIOD
$
1,110,025
$
86,673
$
1,110,025NON-CASH
INVESTING AND FINANCING ACTIVITIESSTOCK
ISSUED UPON CONVERSION OF NOTE PAYABLE
$
150,000
$
-
$
150,000FORGIVENESS
OF RELATED PARTY NOTE; APPLIED TO PAID IN CAPITAL
$
-
$
39,000
$
39,000


(See
accompanying notes)


Statement 4 ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Statement of
Stockholders Deficit (Unaudited) From
January 23, 2007 (Inception) to March 31, 2010  Common
Share
Additional Paid in
Deficit Accumulated
Accumulated Other Stockholders
Total EquityShares
Amount
For period
DuringPeriod
Income
(Deficit)BALANCE,
JANUARY 23, 2007
-
$
-
$
-
$
-
$
-
$
-Common
shares issued for cash, assets and expenses at $.00075 per share
21,430,200
21,430
(5,350)
-
-
16,080Capital
contribution of expenses
-
-
47,184
-
-
47,184Loss
during the period from inception toDecember 31,
2007
-
-
-
(91,391)
-
(91,391)Foreign
currency translation adjustments
-
-
-
-
455
455BALANCE,
DECEMBER 31, 2007
21,430,200
21,430
41,834
(91,391)
455
(27,672)Capital
contribution of expenses
-
-
47,639
-
-
47,639Loss
during year (2008)
-
-
-
(84,877)
-
(84,877)Foreign
currency translation adjustments
-
-
-
-
(75)
(75)BALANCE,
DECEMBER 31, 2008
21,430,200
21,430
89,473
(176,268)
380
(64,985)Foreign
currency translation adjustments
-
-
-
-
(380)
(380)Loss
during year (2009)
-
-
-
(28,255)

(28,255)BALANCE,
DECEMBER 31, 2009
21,430,200
21,430
89,473
(204,523)
NIL
(93,620)Common
shares issued for cash
3,733,468
3,733
1,096,267
-
-
1,100,000Common
shares issued for assets
21,430,200
21,430
(21,430)


-Common
shares issued on conversion of



-
-note
payable
166,666
167
149,833


150,000Loss
during quarter


-
(67,478)
-
(67,478)BALANCE,
MARCH 31, 2010
46,760,534
$
46,760
$
1,314,143
$
(272,001)
$
NIL
$
1,088,902


(See
accompanying notes)


ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements (Unaudited) March
31, 2010  1. BASIS
OF FINANCIAL STATEMENT PRESENTATION The
accompanying unaudited condensed financial statements have been prepared by the
Company pursuant to the rules and regulations of the Securities and Exchange
Commission.  Certain information and footnote disclosures normally included
in financial statements prepared in accordance with U.S. generally accepted
accounting principles have been condensed or omitted in accordance with such
rules and regulations.  The information furnished in the interim condensed
financial statements includes normal recurring adjustments and reflects all
adjustments, which, in the opinion of management, are necessary for a fair
presentation of such financial statements.  Although management believes
the disclosures and information presented are adequate to make the information
not misleading, it is suggested that these interim condensed financial
statements be read in conjunction with the Company's audited financial
statements and notes thereto included in its Form 10-K filed on March 31, 2009.
 Operating results for the three months ended March 31, 2010 are not
necessarily indicative of the results to be expected for the fiscal year ended
December 31, 2010.  2. ORGANIZATION The
company was originally incorporated under the name of Big Bear Resources Inc. a
USA Company registered in the State of Nevada on January 23, 2007.
  The Company changed its name to Uranium Plus Resources Inc. on March
21, 2008.  Following the acquisition of the business of ArtVentive Inc. the
Company changed its name on January 26, 2010, from Uranium Plus Resources Inc.
to ArtVentive Medical Group, Inc.  The
Company is a medical device corporation, focused on developing, manufacturing
and marketing a family of endoluminal occlusion devices (EOS).  Through its
innovative, proprietary technology the Company has developed unique minimally
invasive occlusion devices and procedures, bringing the current interventional,
image guided techniques to a new level of sophistication, potentially resolving
significant and unaddressed health issues. The EOS device being developed by the
Company targets a substantive market demand in several major clinical areas,
including women's health, peripheral and neurological vascular disorders, and
interventional cardiology procedures.  To
date, the Companys activities have been limited to its formation, corporate
operations and the raising of equity capital.  3. SIGNIFICANT
ACCOUNTING POLICIES USE
OF ESTIMATES The
preparation of the Companys financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions that affect the reported amounts of assets and
liabilities and disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amount of revenues and expenses during
the reporting period.  Actual results could differ from those estimates.
 The Companys periodic filings with the Securities and Exchange Commission
include, where applicable, disclosures of estimates, assumptions, uncertainties
and markets that could affect the financial statements and future operations of
the Company.         ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements (Unaudited) March
31, 2010   FOREIGN CURRENCY TRANSLATIONS The Companys functional and reporting currency is the US dollar.
 All transactions initiated in other currencies are translated into US
dollars using the exchange rate prevailing on the date of transaction.
 Monetary assets and liabilities denominated in foreign currencies are
translated into the US dollar at the rate of exchange in effect at the balance
sheet date.  Unrealized exchange gains and losses arising from such
transactions are deferred until realization and are included as a separate
component of stockholders equity (deficit) as a component of other
comprehensive income or loss. Upon realization, the amount deferred is
recognized in income in the period when it is realized.  The Company recorded an unrealized foreign currency translation
gain, totaling $0 for the period from January 23, 2007 (Inception) to March 31,
2010, in accumulated other comprehensive income.  Cash and Cash equivalents Cash and cash equivalents consist of funds on deposit with banks.
 The Company has no cash equivalents.  The Company had funds on
deposit of $1,110,025 as at March 31, 2010.  4. CONVERTIBLE NOTE PAYABLE The
Company borrowed $150,000 pursuant to an agreement dated April 29, 2008.
 The loan is payable on demand by the Lender.  The Lender has the
option to convert the loan into common shares of the Company at a rate of 1
common share for each $1 borrowed (150,000 common shares).  In the event repayment is demanded and the Company defaults,
interest at a rate of 8% per annum shall be charged from the date of demand.  All funds are in US dollars.  The note was converted into 166,666 shares at a deemed value per
share of $.90 effective February 22, 2010.  5. SHARE CAPITAL Effective
April 22, 2008, the Company forward-split its issued capital stock on a ratio of
5.8 shares for each one old share.  As a result of this transaction,
11,078,000 shares were issued. Effective February 12, 2010, the Company
forward-split its issued capital stock on a ratio of 1.65 shares for each old
share. As a result of this transaction 8,442,200 shares were issued.  Shares
ValueDecember
31, 2008
1,910,000
$
1,910Issued as a
result of forward-split 4/22/08
11,078,000
11,078Issued as a
result of forward-split 2/12/10
8,442,200
8,442December
31,2009
21,430,200
$
21,430Issued
on conversion of note payable
166,666
$
167       ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) A
Development Stage Company Notes to Financial
Statements (Unaudited) March
31, 2010 Shares
ValueIssued
for purchase of assets
21,430,200
$
21,430Issued
in private placement
3,733,468
3,733March
31, 2010
46,760,534
$
46,760  Consideration
for the issue of additional shares has been charged against additional paid in
capital.  The adjustment has been reflected retroactively.  6. GOING CONCERN AND LIQUIDITY CONSIDERATIONS The
accompanying financial statements have been prepared assuming that the Company
will continue as a going concern, which contemplates, among other things, the
realization of assets and satisfaction of liabilities in the normal course of
business.  As of March 31, 2010, the Company has a working capital balance
of $1,085,513 and an accumulated deficit of $272,001.  In response to these challenges, management intends to raise
additional funds through public or private placement offerings.  The accompanying financial statements do not include any
adjustments that might result from the outcome of this uncertainty.  7. RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS In
June 2009, the FASB established the Accounting Standards Codification
(Codification or ASC) as the source of authoritative accounting principles
recognized by the FASB to be applied by nongovernmental entities in the
preparation of financial statements in accordance with generally accepted
accounting principles in the United States (GAAP).  Rules and
interpretive releases of the Securities and Exchange Commission (SEC) issued
under authority of federal securities laws are also sources of GAAP for SEC
registrants.  Existing GAAP was not intended to be changed as a result of
the Codification, and accordingly the change did not impact our financial
statements.  The ASC does change the way the guidance is organized and
presented.  Statement
of Financial Accounting Standards (SFAS) SFAS No. 166 (ASC Topic 810),
Accounting for Transfers of Financial Assetsan Amendment of FASB Statement No.
140, SFAS No. 167 (ASC Topic 810), Amendments to FASB Interpretation No.
46(R), and SFAS No. 168 (ASC Topic 105), The FASB Accounting Standards
Codification and the Hierarchy of Generally Accepted Accounting Principlesa
replacement of FASB Statement No. 162 were recently issued.  SFAS No. 166,
167, and 168 have no current applicability to the Company or their effect on the
financial statements would not have been significant.  Accounting
Standards Update (ASU) ASU No. 2009-05 (ASC Topic 820), which amends Fair
Value Measurements and Disclosures  Overall, ASU No. 2009-13 (ASC Topic 605),
Multiple- Deliverable
Revenue Arrangements, ASU No. 2009-14 (ASC Topic 985), Certain Revenue
Arrangements that include Software Elements, and various other ASUs No. 2009-2
through ASU No. 2010-19 which contain technical corrections to existing guidance
or affect guidance to specialized industries or entities were recently issued.
 These updates have no current applicability to the Company or their effect
on the financial statements would not have been significant.       ArtVentive
Medical Group Inc. (formerly
Uranium Plus Resource Corporation) Notes to Financial
Statements (Unaudited) March
31, 2010  8. PROVISION FOR INCOME TAXES The
company recognizes the tax effects of transactions in the year in which such
transactions enter into the determination of net income, regardless of when
reported for tax purposes.  Deferred taxes are provided in the financial
statements under ASC Topic 740 to give effect to the resulting temporary
differences which may arise from differences in the bases of fixed assets,
depreciation methods, allowances, and start-up costs based on the income taxes
expected to be payable in future years. Minimal exploration stage deferred tax
assets arising as a result of net operating loss carry forwards have been offset
completely by a valuation allowance due to the uncertainty of their utilization
in future periods.  The Company adopted the provisions of ASC Topic
740Accounting for Uncertainty in Income Taxes, on January 1, 2007.  As a
result of the implementation of ASC 740, the Company recognized no increase in
the liability for unrecognized tax benefits. The
Company has no tax positions at March 31, 2010 or December 31, 2009 for which
the ultimate deductibility is highly certain but for which there is uncertainty
about the timing of such deductibility. The
Company recognizes interest accrued related to unrecognized tax benefits in
interest expense and penalties in operating expenses.  During the three
months ended March 31, 2010 and the year ended December 31, 2009, the Company
recognized no interest and penalties.  The Company had no accruals for
interest and penalties at March 31, 2010 and December 31, 2009.  9. CONTRACTUAL OBLIGATIONS Effective February 27, 2010 the Company has entered into
employments agreements for a Chief executive Officer (CEO) and Chairman of the
Board.  The CEO agreement is for a five year term commencing March 1, 2010
at a base salary of $120,000 per annum.  The agreement includes other
employment benefits.  The Chairman is engaged under a consulting agreement
with a base fee of $100,000 per annum. 10. PURCHASE
AGREEMENT On
January 8, 2010 the Company entered into an asset purchase agreement with
Artventive, Inc. a privately held company.  The Company purchased
substantially all of the assets of Artventive, Inc. which consisted entirely of
patents.  The patents were accounted for under SAB Topic 5G using the
historical cost basis of zero.  The combination was accounted for under ASC
805 as a business combination.  Pro Forma financial information as if the
combination had taken place as of the earliest period presented has not be
included as it is not significant.  11. SUBSEQUENT EVENTS Effective
this quarter, the Company implemented a new FASB accounting pronouncement,Subsequent Events. This standard establishes general standards of
accounting for and disclosure of events that occur after the balance sheet date
but before financial statements are issued. The adoption of this accounting
pronouncement did not impact our financial position or results of operations.
The Company evaluated all events or transactions that occurred after March 31,
2010 up through the date these financial statements were issued.


Item
2.  Managements Discussion and Analysis of Financial Condition and Results
of Operations  ArtVentive Medical Group, Inc. (AVTD or the Company), is a
Nevada Corporation trading on the OTC-BB (symbol AVTD).  On March 21, 2008,
the Company changed its name from Big Bear Resources Inc. to Uranium Plus
Resource Corporation and subsequently on January 26, 2010 the Company changed
its name to ArtVentive Medical Group, Inc.  Prior
to March 2008, the Companyhad acquired an option
to acquire a 100% interest in a mineral claim located in the Slocan Mining
Division in the Province of British Columbia, Canada (the Big Bear mineral
claim).  Following careful review, the Company decided to not move forward
and instead pursue molybdenum, gold and two uranium properties located in
Peru.  Management entered into a consulting agreement with Dr. Allan P.
Juhas Ph.D., an Economic Geologist residing in the USA, with extensive
experience in international property evaluation and mineral exploration.
 Dr. Juhas and his team traveled to Peru and visited two of the Companys
proposed properties.  The Manantiel molybdenum prospect was located in the
Shiran district of the Otuzco municipality of La Libertad and the El Zorro gold
prospect consisting of 600 hectares was located 156 kilometers north east of
Trujillo, Peru.  Following receipt of the geological reports and sample
analysis, management decided not to move forward with the further exploration of
these properties.  The
Company had previously evaluated property north of Lima, Peru, and an additional
property in the Province of Corongo.  On
January 26, 2010 the Company changed its name from Uranium Plus Resources, Inc.
to ArtVentive Medical Group, Inc. following the acquisition of substantially all
of the assets of ArtVentive Inc., a California company.  The
Company is currently a medical device corporation, focused on developing,
manufacturing and marketing a family of Endoluminal Occlusion devices (EOS).
 The Company, through its proprietary technology has developed minimally
invasive occlusion devices and procedures, bringing the current interventional,
image guided techniques to a new level of sophistication, resolving potentially
significant and unaddressed health issues.  The EOS device is being
developed by the Company to target market demand in several major clinical
areas, including women's health, peripheral and neurological vascular disorders,
and interventional cardiology procedures.  The
Company has and expects to contract with specific American corporations and
consulting groups to assist in the implementation of an ongoing strategic plan
for the successful international launch, market development, commercialization
and manufacturing of Companys products.  The Company has entered into an
agreement with the Chicago, Illinois based Medical Murray Inc., a leader in the
field of medical device development and manufacturing.  Medical Murray Inc.
is recognized as being ISO certified and FDA registered.  Also the Company
has entered in to an agreement with the Northwest Clinical Research Group, Inc.,
located Seattle, Washington.  This group will play a role in building the
complex infrastructure and support





necessary for outlining the regulatory and clinical strategy, in
addition to providing a full platform of quality controls parallel and
synergistic to what Medical Murray is providing.  Their responsibility also
extends to encompass communication with the FDA and European Notified Body (FDA
counterpart).  The
Company is focused on the continued development and implementation of its
proprietary line of lumen occlusion devices in defining new opportunity within
the medical device arena.  .  To
date, the Companys activities have been limited to its formation, corporate
operations, the raising of equity capital and executing the business of the
Company as laid out in the Business Plan of the Company.  For the
three months ended March 31, 2010, the Company incurred continuing general and
administrative costs of $58,260, and research and development costs of $10,000.
 Costs for the same period in 2009 were $10,555 and $0, respectively.
 The increase in expenses was due to work on the development of its medical
device.  Item
3. Quantitative and Qualitative Disclosure about Market Risk  Not
required by smaller reporting companies.  Item 4T.
 Controls and Procedures  As of
the end of the period covered by this report, AVTD carried out an evaluation of
the effectiveness of the Companys disclosure controls and procedures (as
defined by Rule 13-15(f) and 15d-15(f) under the Securities Exchange Act of
1934) under the supervision and with the participation of ArtVentive Medical
Groups President and Chief Financial Officer.  Based on and as of the date
of such evaluation, the aforementioned officers have concluded that ArtVentive
Groups disclosure controls and procedures were not effective in recording,
processing, summarizing and reporting, on a timely basis, information required
to be disclosed by us in the reports that we file or submit under the Exchange
Act.  AVTD
also maintains a system of internal accounting controls that is designed to
provide assurance that assets are safeguarded and that transactions are executed
in accordance with managements authorization and properly recorded. This system
is continually reviewed and is augmented by written policies and procedures, the
careful selection and training of qualified personnel and an internal audit
program to monitor its effectiveness.  There
were no significant changes in AVTDs internal controls or in other factors that
could significantly affect these controls during the quarter ended March 31,
2010.  There were no significant deficiencies or material weaknesses, and
therefore there were no corrective actions taken.  It should be noted that
any system of controls, however well designed and operated, can provide only
reasonable, and not absolute, assurance that the objectives of the system are
met. In addition, the design of any control system is based in part upon certain
assumptions about the likelihood of future events. Because of these and other
inherent limitations of control systems,





there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions, regardless of
how remote.





PART II  INFORMATION  Item
1.  Legal Proceedings  None  Item
2.  Unregistered Sales of Equity Securities and Use of Proceeds  None  Item
3.  Defaults Upon Senior Securities  None  Item
4.  Submission of Matters to a Vote of Security Holders  None.  Item
5.  Other Information  None  Item 6.
 Exhibits  Exhibit No.
Document
Location31
Rule
13a-41(a)/15d-14(a) Certifications
Included32
Section
1350 Certifications
Included





SIGNATURES  In accordance with
the requirements of the Exchange Act, the registrant caused this report to be
signed on its behalf by the undersigned, thereunto duly authorized.  ARTVENTIVE MEDICAL
GROUP, INC.  May 24, 2010   /s/ Dr. Leon
Rudakov Dr. Leon Rudakov Chief Executive
Officer   /s/ H. James
Graham H. James Graham President